Full-time · Boulder, United States
Who We Are
Cogent Biosciences is a publicly traded biotechnology company developing real solutions to treat genetically driven diseases. With a focus on rational drug discovery and development, we are leveraging validated biology to advance precision therapies designed to address the true underlying drivers of disease and provide real hope for patients. Cogent’s lead therapeutic candidate, bezuclastinib (CGT9486), is a precision kinase inhibitor designed to selectively and potently inhibit the KIT D816V mutation. This mutation is responsible for driving a rare and serious condition called Systemic Mastocytosis (SM), which can severely impact many different tissues and organs in the body. We are also studying CGT9486 to treat advanced gastrointestinal stromal tumors (GIST), which have a strong dependence on oncogenic KIT signaling. We are currently enrolling two Phase 2 clinical trials for patients with SM and a global Phase 3 trial for GIST patients.
This position works with a fast-paced team in Drug Discovery and Development to support DMPK activities such as providing quantitative bioanalysis, outsourcing in vitro ADME assays, and compiling in vitro and in vivo data for dissemination to the larger oncology team. The successful candidate will utilize their strong LC-MS skills and ADME/PK data to collaborate cross-functionally with in-house medicinal chemistry, pharmacology and toxicology teams and outside CROs.
Responsibilities
Qualifications
Open roles at Cogent Biosciences